Nasdaq atai.

Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business. ... ATAI Life Sciences NV (NASDAQ:ATAI) 1.07. Delayed Data. As of 3:58pm ET -0.055 ...Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.ATAI Life Sciences N.V. (NASDAQ:ATAI)’s traded shares stood at 0.58 million during the last session, with the company’s beta value hitting 0.86. At the close of trading, the stock’s price was $1.32, to imply an increase of 6.45% or $0.08 in intraday trading. The ATAI share’s 52-week high ...Nov 30, 2023 · Atai Life Sciences (NASDAQ:ATAI) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior business?We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.

Jul 14, 2021 · Some of the companies already making a big splash in the as yet small sector include COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), and Seelos Therapeutics, Inc ... Alcohol use disorder. Treatment-resistant depression. Opiate withdrawal syndrome. PTSD. Social anxiety in autistic adults. Anxiety with a life-threatening illness. Generalized anxiety disorder ...Here are our picks for the five psychedelic companies to watch in 2022: Atai Life Sciences, Berlin, Germany – listed on NASDAQ (ATAI) since July, 2021 – Market cap $999 million. Atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is also one of the largest shareholders ...

Nov 14, 2023 · NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...

We have applied to list our common shares on the Nasdaq Global Market under the symbol “ATAI.” We are an “emerging growth company” as defined under the U.S. ...Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. ... Nasdaq Insider Activity page provides trading information of corporate insiders (officers ...NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...In this week’s Trade To Black Podcast, TDR Founder Shadd Dales and lead financial writer Benjamin A. Smith interview the founder of Apeiron Investment Group, Christian Angermayer.Aperion is best known in North America for its prominent investments in psychedelic biopharma leaders atai Life Sciences N.V. (NASDAQ: ATAI) and …Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR ...

COMPASS Pathways (NASDAQ:CMPS), GH Research (NASDAQ:GHRS), atai Life Sciences (NASDAQ:ATAI), IntelGenx Technologies (OTCQB:IGXT) and Filament Health (OTCQB:FLHLF) reported their first quarter ...

To date, the VC focus on psychedelics hasn’t proven much of a return on investment. FDA approval of drugs like psilocybin and MDMA is likely years away. The stock price of psychedelic therapy companies has tanked in recent years. In March 2023, Atai Life Sciences noted that it had laid off roughly 30% of its employees.senior director of external affairs @ atai life sciences (nasdaq: atai ...Shares in Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling back some.atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023.8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...

Follow. NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of ...Follow. NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of ...Atai Life Sciences (NASDAQ:ATAI) closed at $1.29, almost the same as Friday 22’s closing price $1.30 and also down from past weeks’ closings ($1.45 and $1.43.)BEIJING, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ATA Inc. ("ATA" or the "Company", Nasdaq: ATAI), a company focused on providing students with quality educational experiences and services in China and ...Atai Life Sciences N.V. (NASDAQ: ATAI) took a significant step to bolster its partnership with IntelGenx Technologies Corp. . The medical technology firm, Atai, now owns a substantial 63% stake in ...Atai Life Sciences (NASDAQ:ATAI) is one of the leading biotech companies discovering and developing treatments derived from psychedelic compounds.Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis.

ATAI Life Sciences Stock (NASDAQ:ATAI), Guidance and Forecast benzinga.com - August 13 at 4:19 AM: ATAI Life Sciences Stock (NASDAQ:ATAI), Short Interest Report benzinga.com - August 12 at 11:19 PM: ATAI Life Sciences (ATAI) Receives a Buy from Berenberg Bank markets.businessinsider.com - August 11 at 5:09 PM

The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.Analyst's Opinion · Consensus Rating. Atai Life Sciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...Dec 1, 2023 · ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101 ... Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7. Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders.(NASDAQ: ATAI) Atai Life Sciences Nv's forecast annual revenue growth rate of 69.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.06%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.63%.Atai Life Sciences N.V. (Nasdaq: ATAI) announced positive initial results for their Phase 1 clinical trial of KUR-101. KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD).Sep 21, 2021 · NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...

Ticker Symbol: ATAI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $15.00: CIK Code: 0001840904: CUSIP Number: N0731H103 ...

Atai. On April 7, 2021, Atai Life Sciences , (NASDAQ: ATAI) a clinical-stage biopharmaceutical company developing psychedelics and non-psychedelic compounds for mental health wellness, acquired a majority stake in Delaware-based Psyber, a company working on a brain-to-computer (BCI) interface device. It is hoped that the Psyber brain-to ...

Oct 12, 2022 · NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR ... NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ('atai' or the 'Company'), a global biotech company developing psychedelic and non-psyc... NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a gl...Oct 5, 2022 · - atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine ... Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis.atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently ...October 6, 2023. NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inau... atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ...NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.senior director of external affairs @ atai life sciences (nasdaq: atai ...Nov 10, 2022 · atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ...

He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of ...Atai Life Sciences N.V. (ATAI) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.1000 +0.0100 (+0.92%) At close: 01:00PM EST. 1.1400 +0.04 (+3.64%) After hours: 04:54PM... Apr 13, 2023 · atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been ... ATAI Life Sciences N.V. (NASDAQ:ATAI) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...Instagram:https://instagram. lemonade stocksssdi vs social security retirementwhen can we pre order iphone 15autoazone NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders ...Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in the first quarter of 2023. nhwkt rowe price etf list One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis. forex trading course reviews (RTTNews) - atai Life Sciences N.V. (ATAI) reported additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. KUR-101 was well tolerated and showed ...NASDAQ Health Care/Life Sciences Compare to Open 1.08 Prior Close 1.04 (11/30/23) 1 Day ATAI 7.21% DJIA 0.30% Russell 2K 1.41% Health Care/Life Sciences 0.38% Overview Per-Share Earnings,...